Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (Nature Communications, (2019), 10, 1, (2484), 10.1038/s41467-019-10127-x)

Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, Cheng Ean Chee, Soo Chin Lee, Kam Man Hui, Jie Li, Yeoh Khay Guan, Wei Peng Yong, Jimmy So, Wee Joo Chng, Chin Hin Ng, Jianbiao Zhou, Ling Zhi Wang, John Shyi Peng Yuen, Henry Sun Sien Ho, Sim Mei Yi, Edmund Chiong, Su Pin Choo, Joanne NgeowMatthew Chau Hsien Ng, Clarinda Chua, Eugene Shen Ann Yeo, Iain Bee Huat Tan, Joel Xuan En Sng, Nicholas Yan Zhi Tan, Jean Paul Thiery, Boon Cher Goh, Qi Zeng*

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (Nature Communications, (2019), 10, 1, (2484), 10.1038/s41467-019-10127-x)'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases